Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant

被引:48
作者
Hasegawa, H
Ichinohe, T
Strong, P
Watanabe, I
Ito, S
Tamura, S
Takahashi, H
Sawa, H
Chiba, J
Kurata, T
Sata, T
机构
[1] Natl Inst Infect Dis, Dept Pathol, Tokyo 2080011, Japan
[2] Tokyo Univ Sci, Dept Biol Sci & Technol, Noda, Chiba 278, Japan
[3] Univ Oxford, MRC, Immunochem Unit, Oxford, England
[4] Osaka Univ, Res Inst Microbial Dis, Lab Prevent Viral Dis, Osaka, Japan
[5] Hokkaido Univ, Cent COE Program Zoonosis Control 21, Lab Mol & Cellular Pathol, Sapporo, Hokkaido, Japan
[6] CREST, JST, Sapporo, Hokkaido, Japan
关键词
influenza; chitin microparticles; nasal vaccine; adjuvant; IgA;
D O I
10.1002/jmv.20247
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Chitin in the form of microparticles (chitin microparticles, CMP) has been demonstrated to be a potent stimulator of macrophages, promoting T-helper-1 (Th1) activation and cytokine response. In order to examine the mucosal adjuvant effect of CMP co-administered with influenza hemagglutinin (HA) vaccine against influenza infection, CMP were intranasally co-administered with influenza HA vaccine prepared from PR8 (H1N1) virus. Inoculation of the vaccine with CMP induced primary and secondary anti-HA IgA responses in the nasal wash and anti-HA IgG responses in the serum, which were significantly higher than those of nasal vaccination without CMP, and provided a complete protection against a homologous influenza virus challenge in the nasal infection influenza model. In addition, CMP-based immunization using A/Yamagata (H1N1) and A/Guizhou (H3N2) induced PR8 HA-reactive IgA in the nasal washes and specific-IgG in the serum. The immunization with A/Yamagata and CMP resulted in complete protection against a PR8 (H1N1) challenge in A/Yamagata (H1N1)-vaccinated mice, while that with A/Guizhou (H3H2) and CMP exhibited a 100-fold reduction of nasal virus titer, demonstrating the cross-protective effect of CMP and influenza vaccine. It is suggested that CMP provide a safe and effective adjuvant for nasal vaccination with inactivated influenza vaccine. (C) 2005 Wiley-Liss, Inc.
引用
收藏
页码:130 / 136
页数:7
相关论文
共 39 条
[1]   Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines [J].
Asahi, Y ;
Yoshikawa, T ;
Watanabe, I ;
Iwasaki, T ;
Hasegawa, H ;
Sato, Y ;
Shimada, S ;
Nanno, M ;
Matsuoka, Y ;
Ohwaki, M ;
Iwakura, Y ;
Suzuki, Y ;
Aizawa, C ;
Sata, T ;
Kurata, T ;
Tamura, S .
JOURNAL OF IMMUNOLOGY, 2002, 168 (06) :2930-2938
[2]   Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens [J].
Bacon, A ;
Makin, J ;
Sizer, PJ ;
Jabbal-Gill, I ;
Hinchcliffe, M ;
Illum, L ;
Chatfield, S ;
Roberts, M .
INFECTION AND IMMUNITY, 2000, 68 (10) :5764-5770
[3]   DOSE-RESPONSE OF A/ALASKA/6/77 (H3N2) COLD-ADAPTED REASSORTANT VACCINE VIRUS IN ADULT VOLUNTEERS - ROLE OF LOCAL ANTIBODY IN RESISTANCE TO INFECTION WITH VACCINE VIRUS [J].
CLEMENTS, ML ;
ODONNELL, S ;
LEVINE, MM ;
CHANOCK, RM ;
MURPHY, BR .
INFECTION AND IMMUNITY, 1983, 40 (03) :1044-1051
[4]   IMMUNITY TO INFLUENZA IN MAN [J].
COUCH, RB ;
KASEL, JA .
ANNUAL REVIEW OF MICROBIOLOGY, 1983, 37 :529-549
[5]  
DAVENPORT FM, 1964, J LAB CLIN MED, V63, P5
[6]   Effects of intranasal administration of cholera toxin (or Escherichia coli heat-labile enterotoxin) B subunits supplemented with a trace amount of the holotoxin on the brain [J].
Hagiwara, Y ;
Iwasaki, T ;
Asanuma, H ;
Sato, Y ;
Sata, T ;
Aizawa, C ;
Kurata, T ;
Tamura, S .
VACCINE, 2001, 19 (13-14) :1652-1660
[7]   Mutants of cholera toxin as an effective and safe adjuvant for nasal influenza vaccine [J].
Hagiwara, Y ;
Komase, K ;
Chen, Z ;
Matsuo, K ;
Suzuki, Y ;
Aizawa, C ;
Kurata, T ;
Tamura, S .
VACCINE, 1999, 17 (22) :2918-2926
[8]   IMMUNITY TO INFLUENZA-A VIRUS-INFECTION IN YOUNG-CHILDREN - A COMPARISON OF NATURAL INFECTION, LIVE COLD-ADAPTED VACCINE, AND INACTIVATED VACCINE [J].
JOHNSON, PR ;
FELDMAN, S ;
THOMPSON, JM ;
MAHONEY, JD ;
WRIGHT, PF .
JOURNAL OF INFECTIOUS DISEASES, 1986, 154 (01) :121-127
[9]   Mutants of Escherichia coli heat-labile enterotoxin as an adjuvant for nasal influenza vaccine [J].
Komase, K ;
Tamura, S ;
Matsuo, K ;
Watanabe, K ;
Hattori, N ;
Odaka, A ;
Suzuki, Y ;
Kurata, T ;
Aizawa, C .
VACCINE, 1998, 16 (2-3) :248-254
[10]  
KRIS RM, 1985, J IMMUNOL, V134, P1230